Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia?

Seminars in Cancer Biology

Volumn 20, Issue 3, 2010, Pages 178-185

  Tavor, Sigal ^a   Petit, Isabelle ^b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b INSERM   (France)

Author keywords

ALL; AML; CXCR4; LSC; SDF 1

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4 ANTIBODY; DIMETHYLAMINOPARTHENOLIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERMES ANTIGEN; INTERLEUKIN 3 RECEPTOR ALPHA ANTIBODY; MONOCLONAL ANTIBODY; N [1,4,8,11 TETRAAZACYCLOTETRADECANYL 1,4 PHENYLENEBIS(METHYLENE)] 2 (AMINOMETHYL)PYRIDINE; NEUTRALIZING ANTIBODY; PARTHENOLIDE; PLERIXAFOR; STROMAL CELL DERIVED FACTOR 1; T 140; TC 14012; TERPENOID; TN 14003; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW CELL; CANCER STEM CELL; CLINICAL TRIAL; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMIA CELL; LEUKEMIA RELAPSE; LEUKEMOGENESIS; NONHUMAN; PROGNOSIS; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; TUMOR MICROENVIRONMENT;

ACUTE DISEASE; ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW; CHEMOKINE CXCL12; HUMANS; LEUKEMIA; MODELS, BIOLOGICAL; NEOPLASTIC STEM CELLS; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; STEM CELL NICHE; TUMOR MICROENVIRONMENT;

EID: 77956620024     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2010.07.001     Document Type: Review

References (116)

1. Dick J. Stem cell concepts renew cancer research. Blood 2008, 112:4793-4807.
2. McCulloch E., Buick R., Curtis J., Messner H., Senn J. The heritable nature of clonal characteristics in acute myeloblastic leukemia. Blood 1981, 58:105-109.
3. McCulloch E. Stem cells in normal and leukemic hemopoiesis (Henry Stratton Lecture, 1982). Blood 1983, 62:1-13.
4. Bonnet D., Dick J. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
5. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
6. Larochelle A., Vormoor J., Hanenberg H., Wang J., Bhatia M., Lapidot T., et al. Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy. Nat Med 1996, 2:1329-1337.
7. + subpopulations. Blood 1995, 86:2906-2912.
8. Jordan C., Upchurch D., Szilvassy S., Guzman M., Howard D., Pettigrew A., et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000, 14:1777-1784.
9. Jaiswal S., Jamieson C., Pang W., Park C., Chao M., Majeti R., et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 2009, 138:271-285.
10. Legras S., Günthert U., Stauder R., Curt F., Oliferenko S., Kluin-Nelemans H., et al. A strong expression of CD44-6v correlates with shorter survival of patients with acute myeloid leukemia. Blood 1998, 91:3401-3413.
11. Testa U., Riccioni R., Militi S., Coccia E., Stellacci E., Samoggia P., et al. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood 2002, 100:2980-2988.
12. Majeti R., Chao M., Alizadeh A., Pang W., Jaiswal S., Gibbs K.J., et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009, 138:286-299.
13. de Jonge-Peeters S.D., Kuipers F., de Vries E.G., Vellenga E. ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. Crit Rev Oncol Hematol 2007, 62:214-226.
14. Steelman L., Abrams S., Whelan J., Bertrand F., Ludwig D., Bäsecke J., et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 2008, 22:686-707.
15. Guzman M., Neering S., Upchurch D., Grimes B., Howard D., Rizzieri D., et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001, 98:2301-2307.
16. Hong D., Gupta R., Ancliff P., Atzberger A., Brown J., Soneji S., et al. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science 2008, 319:336-339.
17. + in B-lineage childhood acute lymphoblastic leukemia. Haematologica 2010, 95:679-683.
18. Bernt K., Armstrong S. Leukemia stem cells and human acute lymphoblastic leukemia. Semin Hematol 2009, 46:33-38.
19. Cozzio A., Passegué E., Ayton P., Karsunky H., Cleary M., Weissman I. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 2003, 17:3029-3035.
20. Huntly B., Shigematsu H., Deguchi K., Lee B., Mizuno S., Duclos N., et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 2004, 6:587-596.
21. Krivtsov A., Twomey D., Feng Z., Stubbs M., Wang Y., Faber J., et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006, 442:818-822.
22. Minden M., Till J., McCulloch E. Proliferative state of blast cell progenitors in acute myeloblastic leukemia (AML). Blood 1978, 52:592-600.
23. Guan Y., Gerhard B., Hogge D. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 2003, 101:3142-3149.
24. Calvi L., Adams G., Weibrecht K., Weber J., Olson D., Knight M., et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003, 425:841-846.
25. Zhang J., Niu C., Ye L., Huang H., He X., Tong W., et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003, 425:836-841.
26. Kopp H., Avecilla S., Hooper A., Rafii S. The bone marrow vascular niche: home of HSC differentiation and mobilization. Physiology (Bethesda) 2005, 20:349-356.
27. Kiel M., Morrison S. Uncertainty in the niches that maintain haematopoietic stem cells. Nat Rev Immunol 2008, 8:290-301.
28. Sugiyama T., Kohara H., Noda M., Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006, 25:977-988.
29. Ara T., Tokoyoda K., Sugiyama T., Egawa T., Kawabata K., Nagasawa T. Long-term hematopoietic stem cells require stromal cell-derived factor-1 for colonizing bone marrow during ontogeny. Immunity 2003, 19:257-267.
30. + cells through Wnt signaling. Nat Immunol 2007, 8:1123-1131.
31. Katayama Y., Battista M., Kao W., Hidalgo A., Peired A., Thomas S., et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell 2006, 124:407-421.
32. Eliasson P., Jönsson J. The hematopoietic stem cell niche: low in oxygen but a nice place to be. J Cell Physiol 2010, 222:17-22.
33. Prosper F., Verfaillie C. Regulation of hematopoiesis through adhesion receptors. J Leukoc Biol 2001, 69:307-316.
34. Wilson A., Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol 2006, 6:93-106.
35. McCulloch E.A., Siminovitch L., Till J.E., Russell E.S., Bernstein S.E. The cellular basis of the genetically determined hemopoietic defect in anemic mice of genotype Sl-Sld. Blood 1965, 26:399-410.
36. Czechowicz A., Kraft D., Weissman I., Bhattacharya D. Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches. Science 2007, 318:1296-1299.
37. Kiel M., Acar M., Radice G., Morrison S. Hematopoietic stem cells do not depend on N-cadherin to regulate their maintenance. Cell Stem Cell 2009, 4:170-179.
38. Hosokawa K., Arai F., Yoshihara H., Iwasaki H., Hembree M., Yin T., et al. Cadherin-based adhesion is a potential target for niche manipulation to protect hematopoietic stem cells in adult bone marrow. Cell Stem Cell 2010, 6:194-198.
39. Nilsson S., Johnston H., Whitty G., Williams B., Webb R., Denhardt D., et al. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood 2005, 106:1232-1239.
40. Arai F., Hirao A., Ohmura M., Sato H., Matsuoka S., Takubo K., et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 2004, 118:149-161.
41. Zou Y., Kottmann A., Kuroda M., Taniuchi I., Littman D. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998, 393:595-599.
42. Tachibana K., Hirota S., Iizasa H., Yoshida H., Kawabata K., Kataoka Y., et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998, 393:591-594.
43. Peled A., Petit I., Kollet O., Magid M., Ponomaryov T., Byk T., et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999, 283:845-848.
44. Kollet O., Spiegel A., Peled A., Petit I., Byk T., Hershkoviz R., et al. Rapid and efficient homing of human CD34(+)CD38(-/low)CXCR4(+) stem and progenitor cells to the bone marrow and spleen of NOD/SCID and NOD/SCID/B2m(null) mice. Blood 2001, 97:3283-3291.
45. Peled A., Kollet O., Ponomaryov T., Petit I., Franitza S., Grabovsky V., et al. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(+) cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood 2000, 95:3289-3296.
46. + stem/progenitor cells to bone marrow. Blood 2004, 103:2981-2989.
47. Méndez-Ferrer S., Lucas D., Battista M., Frenette P. Haematopoietic stem cell release is regulated by circadian oscillations. Nature 2008, 452:442-447.
48. Liles W., Broxmeyer H., Rodger E., Wood B., Hübel K., Cooper S., et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003, 102:2728-2730.
49. Lataillade J., Clay D., Dupuy C., Rigal S., Jasmin C., Bourin P., et al. Chemokine SDF-1 enhances circulating CD34(+) cell proliferation in synergy with cytokines: possible role in progenitor survival. Blood 2000, 95:756-768.
50. Broxmeyer H., Kohli L., Kim C., Lee Y., Mantel C., Cooper S., et al. Stromal cell-derived factor-1/CXCL12 directly enhances survival/antiapoptosis of myeloid progenitor cells through CXCR4 and G(alpha)i proteins and enhances engraftment of competitive, repopulating stem cells. J Leukoc Biol 2003, 73:630-638.
51. Rosu-Myles M., Bhatia M. SDF-1 enhances the expansion and maintenance of highly purified human hematopoietic progenitors. Hematol J 2003, 4:137-145.
52. Broxmeyer H., Cooper S., Kohli L., Hangoc G., Lee Y., Mantel C., et al. Transgenic expression of stromal cell-derived factor-1/CXC chemokine ligand 12 enhances myeloid progenitor cell survival/antiapoptosis in vitro in response to growth factor withdrawal and enhances myelopoiesis in vivo. J Immunol 2003, 170:421-429.
53. Hérodin F., Bourin P., Mayol J., Lataillade J., Drouet M. Short-term injection of antiapoptotic cytokine combinations soon after lethal gamma-irradiation promotes survival. Blood 2003, 101:2609-2616.
54. Ponomaryov T., Peled A., Petit I., Taichman R., Habler L., Sandbank J., et al. Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest 2000, 106:1331-1339.
55. Janowska-Wieczorek A., Marquez L., Dobrowsky A., Ratajczak M., Cabuhat M. Differential MMP and TIMP production by human marrow and peripheral blood CD34(+) cells in response to chemokines. Exp Hematol 2000, 28:1274-1285.
56. + progenitor cells. J Clin Invest 2005, 115:168-176.
57. Busillo J., Armando S., Sengupta R., Meucci O., Bouvier M., Benovic J. Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling. J Biol Chem 2010, 285:7805-7817.
58. Burns J., Summers B., Wang Y., Melikian A., Berahovich R., Miao Z., et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006, 203:2201-2213.
59. Sierro F., Biben C., Martínez-Muñoz L., Mellado M., Ransohoff R., Li M., et al. Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc Natl Acad Sci USA 2007, 104:14759-14764.
60. Ishikawa F., Yoshida S., Saito Y., Hijikata A., Kitamura H., Tanaka S., et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007, 25:1315-1321.
61. Saito Y., Uchida N., Tanaka S., Suzuki N., Tomizawa-Murasawa M., Sone A., et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol 2010, 28:275-280.
62. Mortensen B., Jensen P., Helledie N., Iversen P., Ralfkiaer E., Larsen J., et al. Changing bone marrow micro-environment during development of acute myeloid leukaemia in rats. Br J Haematol 1998, 102:458-464.
63. Wellmann S., Guschmann M., Griethe W., Eckert C., von Stackelberg A., Lottaz C., et al. Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF. Leukemia 2004, 18:926-933.
64. Colmone A., Amorim M., Pontier A., Wang S., Jablonski E., Sipkins D. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science 2008, 322:1861-1865.
65. Mowafi F., Cagigi A., Matskova L., Björk O., Chiodi F., Nilsson A. Chemokine CXCL12 enhances proliferation in pre-B-ALL via STAT5 activation. Pediatr Blood Cancer 2008, 50:812-817.
66. Mirshahi P., Rafii A., Vincent L., Berthaut A., Varin R., Kalantar G., et al. Vasculogenic mimicry of acute leukemic bone marrow stromal cells. Leukemia 2009, 23:1039-1048.
67. Hussong J., Rodgers G., Shami P. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000, 95:309-313.
68. Koomagi R., Zintl F., Sauerbrey A., Volm M. Vascular endothelial growth factor in newly diagnosed and recurrent childhood acute lymphoblastic leukemia as measured by real-time quantitative polymerase chain reaction. Clin Cancer Res 2001, 7:3381-3384.
69. Sipkins D., Wei X., Wu J., Runnels J., Côté D., Means T., et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature 2005, 435:969-973.
70. Walkley C., Olsen G., Dworkin S., Fabb S., Swann J., McArthur G., et al. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell 2007, 129:1097-1110.
71. Raaijmakers M., Mukherjee S., Guo S., Zhang S., Kobayashi T., Schoonmaker J., et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 2010, 464:852-857.
72. Bendall L., Baraz R., Juarez J., Shen W., Bradstock K. Defective p38 mitogen-activated protein kinase signaling impairs chemotaxic but not proliferative responses to stromal-derived factor-1alpha in acute lymphoblastic leukemia. Cancer Res 2005, 65:3290-3298.
73. Tavor S., Petit I., Porozov S., Avigdor A., Dar A., Leider-Trejo L., et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res 2004, 64:2817-2824.
74. + hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood 1998, 91:4523-4530.
75. Möhle R., Schittenhelm M., Failenschmid C., Bautz F., Kratz-Albers K., Serve H., et al. Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia. Br J Haematol 2000, 110:563-572.
76. Spoo A., Lübbert M., Wierda W., Burger J. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood 2007, 109:786-791.
77. Konoplev S., Rassidakis G., Estey E., Kantarjian H., Liakou C., Huang X., et al. Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer 2007, 109:1152-1156.
78. Fiegl M., Samudio I., Clise-Dwyer K., Burks J., Mnjoyan Z., Andreeff M. CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure. Blood 2009, 113:1504-1512.
79. Petit I., Szyper-Kravitz M., Nagler A., Lahav M., Peled A., Habler L., et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002, 3:687-694.
80. Tavor S., Petit I., Porozov S., Goichberg P., Avigdor A., Sagiv S., et al. Motility, proliferation, and egress to the circulation of human AML cells are elastase dependent in NOD/SCID chimeric mice. Blood 2005, 106:2120-2127.
81. Fukuda S., Broxmeyer H., Pelus L. Flt3 ligand and the Flt3 receptor regulate hematopoietic cell migration by modulating the SDF-1alpha(CXCL12)/CXCR4 axis. Blood 2005, 105:3117-3126.
82. Rombouts E., Pavic B., Löwenberg B., Ploemacher R. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood 2004, 104:550-557.
83. Fazio G., Palmi C., Rolink A., Biondi A., Cazzaniga G. PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells. Cancer Res 2008, 68:181-189.
84. Grundler R., Brault L., Gasser C., Bullock A., Dechow T., Woetzel S., et al. Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration. J Exp Med 2009, 206:1957-1970.
85. Rubin J.B. Chemokine signaling in cancer: one hump or two?. Semin Cancer Biol 2009, 19:116-122.
86. Juarez J., Baraz R., Gaundar S., Bradstock K., Bendall L. Interaction of interleukin-7 and interleukin-3 with the CXCL12-induced proliferation of B-cell progenitor acute lymphoblastic leukemia. Haematologica 2007, 92:450-459.
87. Scupoli M., Donadelli M., Cioffi F., Rossi M., Perbellini O., Malpeli G., et al. Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF-kappaB and JNK/AP-1 pathways. Haematologica 2008, 93:524-532.
88. Spiegel A., Kollet O., Peled A., Abel L., Nagler A., Bielorai B., et al. Unique SDF-1-induced activation of human precursor-B ALL cells as a result of altered CXCR4 expression and signaling. Blood 2004, 103:2900-2907.
89. Shen W., Bendall L., Gottlieb D., Bradstock K. The chemokine receptor CXCR4 enhances integrin-mediated in vitro adhesion and facilitates engraftment of leukemic precursor-B cells in the bone marrow. Exp Hematol 2001, 29:1439-1447.
90. Bradstock K., Makrynikola V., Bianchi A., Shen W., Hewson J., Gottlieb D. Effects of the chemokine stromal cell-derived factor-1 on the migration and localization of precursor-B acute lymphoblastic leukemia cells within bone marrow stromal layers. Leukemia 2000, 14:882-888.
91. Juarez J., Thien M., Dela Pena A., Baraz R., Bradstock K., Bendall L. CXCR4 mediates the homing of B cell progenitor acute lymphoblastic leukaemia cells to the bone marrow via activation of p38MAPK. Br J Haematol 2009, 145:491-499.
92. Liesveld J., Bechelli J., Rosell K., Lu C., Bridger G., Phillips Gn, et al. Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells. Leuk Res 2007, 31:1553-1563.
93. Tavor S., Eisenbach M., Jacob-Hirsch J., Golan T., Petit I., Benzion K., et al. The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation. Leukemia 2008, 22:2151-5158.
94. Jacobi A., Thieme S., Lehmann R., Ugarte F., Malech H., Koch S., et al. Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts. Exp Hematol 2010, 38:180-190.
95. Nagasawa T., Kikutani H., Kishimoto T. Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci USA 1994, 91:2305-2309.
96. Juarez J., Bradstock K., Gottlieb D., Bendall L. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia 2003, 17:1294-1300.
97. Nishii K., Katayama N., Miwa H., Shikami M., Masuya M., Shiku H., et al. Survival of human leukaemic B-cell precursors is supported by stromal cells and cytokines: association with the expression of bcl-2 protein. Br J Haematol 1999, 105:701-710.
98. Bendall L., Daniel A., Kortlepel K., Gottlieb D. Bone marrow adherent layers inhibit apoptosis of acute myeloid leukemia cells. Exp Hematol 1994, 22:1252-1260.
99. Konopleva M., Konoplev S., Hu W., Zaritskey A., Afanasiev B., Andreeff M. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 2002, 16:1713-1724.
100. Matsunaga T., Takemoto N., Sato T., Takimoto R., Tanaka I., Fujimi A., et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 2003, 9:1158-1165.
101. Becker P., Kopecky K., Wilks A., Chien S., Harlan J., Willman C., et al. Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia. Blood 2009, 113:866-874.
102. Peled A., Grabovsky V., Habler L., Sandbank J., Arenzana-Seisdedos F., Petit I., et al. The chemokine SDF-1 stimulates integrin-mediated arrest of CD34(+) cells on vascular endothelium under shear flow. J Clin Invest 1999, 104:1199-1211.
103. Charrad R., Li Y., Delpech B., Balitrand N., Clay D., Jasmin C., et al. Ligation of the CD44 adhesion molecule reverses blockage of differentiation in human acute myeloid leukemia. Nat Med 1999, 5:669-676.
104. Jin L., Hope K., Zhai Q., Smadja-Joffe F., Dick J. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006, 12:1167-1174.
105. McCubrey J., Steelman L., Abrams S., Bertrand F., Ludwig D., Bäsecke J., et al. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 2008, 22:708-722.
106. Guzman M., Rossi R., Neelakantan S., Li X., Corbett C., Hassane D., et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 2007, 110:4427-4435.
107. Jordan C. Can we finally target the leukemic stem cells?. Best Pract Res Clin Haematol 2008, 21:615-620.
108. Jin L., Lee E., Ramshaw H., Busfield S., Peoppl A., Wilkinson L., et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 2009, 5:31-42.
109. Ravandi F. Role of cytokines in the treatment of acute leukemias: a review. Leukemia 2006, 20:563-571.
110. Zeng Z., Shi Y., Samudio I., Wang R., Ling X., Frolova O., et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2009, 113:6215-6224.
111. Nervi B., Ramirez P., Rettig M., Uy G., Holt M., Ritchey J., et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009, 113:6206-6214.
112. Fruehauf S., Veldwijk M.R., Seeger T., Schubert M., Laufs S., Topaly J., et al. A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European Phase II Study. Cytotherapy 2009, 11:992-1001.
113. Burger J., Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009, 23:43-52.
114. Kalatskaya I., Berchiche Y., Gravel S., Limberg B., Rosenbaum J., Heveker N. AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol 2009, 75:1240-1247.
115. Abraham M., Beider K., Wald H., Weiss I.D., Zipori D., Galun E., et al. The CXCR4 antagonist 4F-benzoyl-TN14003 stimulates the recovery of the bone marrow after transplantation. Leukemia 2009, 23:1378-1388.
116. Uy G., Rettig M., McFarland K., Hladnik L., Kulkarni S., Abboud C., et al. Mobilization and Chemosensitization of AML with the CXCR4 Antagonist Plerixafor (AMD3100): a Phase I/II study of AMD3100+MEC in patients with relapsed or refractory disease. Blood 2008, 112. 1944a.